University of Pittsburgh School of Pharmacy, 1004 Salk Hall, Pittsburgh, PA 15261, USA.
Horm Behav. 2011 Nov;60(5):607-16. doi: 10.1016/j.yhbeh.2011.08.010. Epub 2011 Aug 26.
We hypothesize that beneficial effects of estradiol on cognitive performance diminish with age and time following menopause due to a progressive decline in basal forebrain cholinergic function. This study tested whether galanthamine, a cholinesterase inhibitor used to treat memory impairment associated with Alzheimer's disease, could enhance or restore estradiol effects on cognitive performance in aged rats that had been ovariectomized in middle-age. Rats were ovariectomized at 16-17 months of age. At 21-22 months of age rats began receiving daily injections of galanthamine (5mg/day) or vehicle. After one week, half of each group also received 17ß-estradiol administered subcutaneously. Rats were then trained on a delayed matching to position (DMP) T-maze task, followed by an operant stimulus discrimination/reversal learning task. Treatment with galanthamine+estradiol significantly enhanced the rate of DMP acquisition and improved short-term delay-dependent spatial memory performance. Treatment with galanthamine or estradiol alone was without significant effect. Effects were task-specific in that galanthamine+estradiol treatment did not significantly improve performance on the stimulus discrimination/reversal learning task. In fact, estradiol was associated with a significant increase in incorrect responses on this task after reversal of the stimulus contingency. In addition, treatments did not significantly affect hippocampal choline acetyltransferase activity or acetylcholine release. This may be an effect of age, or possibly is related to compensatory changes associated with long-term cholinesterase inhibitor treatment. The data suggest that treating with a cholinesterase inhibitor can enhance the effects of estradiol on acquisition of a DMP task by old rats following a long period of hormone deprivation. This could be of particular benefit to older women who have not used hormone therapy for many years and are beginning to show signs of mild cognitive impairment. Potential mechanisms for these effects are discussed.
我们假设,由于基底前脑胆碱能功能的逐渐下降,雌二醇对认知表现的有益影响会随着绝经后时间的推移而随着年龄的增长而减少。这项研究测试了加兰他敏(一种用于治疗与阿尔茨海默病相关的记忆障碍的胆碱酯酶抑制剂)是否可以增强或恢复中年卵巢切除的老年大鼠的认知表现。大鼠在 16-17 个月大时被卵巢切除。在 21-22 个月大时,大鼠开始每天接受加兰他敏(5mg/天)或载体注射。一周后,每组的一半还接受了皮下给予的 17β-雌二醇。然后,大鼠接受了延迟匹配位置(DMP)T 迷宫任务的训练,然后进行了操作性刺激辨别/反转学习任务。加兰他敏+雌二醇的治疗显著提高了 DMP 的获得速度,并改善了短期延迟依赖的空间记忆表现。单独使用加兰他敏或雌二醇治疗没有显著效果。这些作用是特定于任务的,因为加兰他敏+雌二醇治疗并没有显著改善刺激辨别/反转学习任务的表现。事实上,在刺激条件反转后,雌二醇与该任务中错误反应的显著增加有关。此外,治疗方法并未显著影响海马胆碱乙酰转移酶活性或乙酰胆碱释放。这可能是年龄的影响,也可能与长期使用胆碱酯酶抑制剂治疗相关的代偿性变化有关。数据表明,用胆碱酯酶抑制剂治疗可以增强老年大鼠在长期激素剥夺后对 DMP 任务的获得能力。对于那些多年未使用激素治疗且开始出现轻度认知障碍迹象的老年女性来说,这可能特别有益。讨论了这些影响的潜在机制。